Does the media refer more to OGN or AMPH?

In the previous week, Amphastar Pharmaceuticals had 3 more articles in the media than Organon & Co.. MarketBeat recorded 5 mentions for Amphastar Pharmaceuticals and 2 mentions for Organon & Co.. Organon & Co.'s average media sentiment score of 0.51 beat Amphastar Pharmaceuticals' score of 0.46 indicating that Organon & Co. is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Organon & Co. 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Amphastar Pharmaceuticals 3 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media favor AMPH or TARS?

In the previous week, Amphastar Pharmaceuticals and Amphastar Pharmaceuticals both had 5 articles in the media. Tarsus Pharmaceuticals' average media sentiment score of 0.92 beat Amphastar Pharmaceuticals' score of 0.46 indicating that Tarsus Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Amphastar Pharmaceuticals 3 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Tarsus Pharmaceuticals 1 Very Positive mention(s) 2 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor AMPH or MBX?

In the previous week, Amphastar Pharmaceuticals had 2 more articles in the media than MBX Biosciences. MarketBeat recorded 5 mentions for Amphastar Pharmaceuticals and 3 mentions for MBX Biosciences. Amphastar Pharmaceuticals' average media sentiment score of 0.46 beat MBX Biosciences' score of 0.45 indicating that Amphastar Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Amphastar Pharmaceuticals 3 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral MBX Biosciences 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Amphastar Pharmaceuticals (AMPH) Competitors

$23.62 -0.20 (-0.84%)

Closing price 09/18/2026 04:00 PM Eastern

Extended Trading

$23.62 0.00 (0.00%)

As of 09/18/2026 07:30 PM Eastern

Compare

AMPH vs. OGN, TARS, ARQT, MBX, and MOR

Should you buy Amphastar Pharmaceuticals stock or one of its competitors? Amphastar Pharmaceuticals's main competitors and comparable companies include Organon & Co. (OGN), Tarsus Pharmaceuticals (TARS), Arcutis Biotherapeutics (ARQT), MBX Biosciences (MBX), and MorphoSys (MOR). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "pharmaceuticals" industry.

How does Amphastar Pharmaceuticals compare to Organon & Co.?

Organon & Co. (NYSE:OGN) and Amphastar Pharmaceuticals (NASDAQ:AMPH) are both healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their media sentiment, risk, valuation, earnings, dividends, institutional ownership, profitability and analyst recommendations.

Organon & Co. currently has a consensus target price of $11.40, suggesting a potential downside of 16.70%. Amphastar Pharmaceuticals has a consensus target price of $22.50, suggesting a potential downside of 4.74%. Given Amphastar Pharmaceuticals' stronger consensus rating and higher probable upside, analysts clearly believe Amphastar Pharmaceuticals is more favorable than Organon & Co..

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Organon & Co.	2 Sell rating(s)	5 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.71
Amphastar Pharmaceuticals	2 Sell rating(s)	6 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.75

Organon & Co. has higher revenue and earnings than Amphastar Pharmaceuticals. Amphastar Pharmaceuticals is trading at a lower price-to-earnings ratio than Organon & Co., indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Organon & Co.	$6.22B	0.58	$187M	$0.77	17.77
Amphastar Pharmaceuticals	$719.89M	1.40	$98.09M	$1.69	13.98

In the previous week, Amphastar Pharmaceuticals had 3 more articles in the media than Organon & Co.. MarketBeat recorded 5 mentions for Amphastar Pharmaceuticals and 2 mentions for Organon & Co.. Organon & Co.'s average media sentiment score of 0.51 beat Amphastar Pharmaceuticals' score of 0.46 indicating that Organon & Co. is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Organon & Co.	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Amphastar Pharmaceuticals	3 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

77.4% of Organon & Co. shares are owned by institutional investors. Comparatively, 65.1% of Amphastar Pharmaceuticals shares are owned by institutional investors. 1.6% of Organon & Co. shares are owned by insiders. Comparatively, 29.6% of Amphastar Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Organon & Co. has a beta of 1.52, meaning that its stock price is 52% more volatile than the broader market. Comparatively, Amphastar Pharmaceuticals has a beta of 0.92, meaning that its stock price is 8% less volatile than the broader market.

Amphastar Pharmaceuticals has a net margin of 10.76% compared to Organon & Co.'s net margin of 3.41%. Organon & Co.'s return on equity of 88.97% beat Amphastar Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Organon & Co.	3.41%	88.97%	6.03%
Amphastar Pharmaceuticals	10.76%	14.98%	6.96%

Summary

Amphastar Pharmaceuticals beats Organon & Co. on 8 of the 15 factors compared between the two stocks.

How does Amphastar Pharmaceuticals compare to Tarsus Pharmaceuticals?

Amphastar Pharmaceuticals (NASDAQ:AMPH) and Tarsus Pharmaceuticals (NASDAQ:TARS) are both healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their media sentiment, analyst recommendations, institutional ownership, dividends, earnings, risk, valuation and profitability.

Amphastar Pharmaceuticals presently has a consensus price target of $22.50, suggesting a potential downside of 4.74%. Tarsus Pharmaceuticals has a consensus price target of $94.00, suggesting a potential upside of 20.37%. Given Tarsus Pharmaceuticals' stronger consensus rating and higher probable upside, analysts plainly believe Tarsus Pharmaceuticals is more favorable than Amphastar Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Amphastar Pharmaceuticals	2 Sell rating(s)	6 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.75
Tarsus Pharmaceuticals	1 Sell rating(s)	2 Hold rating(s)	5 Buy rating(s)	2 Strong Buy rating(s)	2.80

65.1% of Amphastar Pharmaceuticals shares are owned by institutional investors. Comparatively, 90.0% of Tarsus Pharmaceuticals shares are owned by institutional investors. 29.6% of Amphastar Pharmaceuticals shares are owned by insiders. Comparatively, 9.6% of Tarsus Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Amphastar Pharmaceuticals has higher revenue and earnings than Tarsus Pharmaceuticals. Tarsus Pharmaceuticals is trading at a lower price-to-earnings ratio than Amphastar Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Amphastar Pharmaceuticals	$719.89M	1.40	$98.09M	$1.69	13.98
Tarsus Pharmaceuticals	$451.36M	7.59	-$66.42M	-$1.09	N/A

In the previous week, Amphastar Pharmaceuticals and Amphastar Pharmaceuticals both had 5 articles in the media. Tarsus Pharmaceuticals' average media sentiment score of 0.92 beat Amphastar Pharmaceuticals' score of 0.46 indicating that Tarsus Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Amphastar Pharmaceuticals	3 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Tarsus Pharmaceuticals	1 Very Positive mention(s)	2 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Amphastar Pharmaceuticals has a beta of 0.92, suggesting that its stock price is 8% less volatile than the broader market. Comparatively, Tarsus Pharmaceuticals has a beta of 0.54, suggesting that its stock price is 46% less volatile than the broader market.

Amphastar Pharmaceuticals has a net margin of 10.76% compared to Tarsus Pharmaceuticals' net margin of -7.67%. Amphastar Pharmaceuticals' return on equity of 14.98% beat Tarsus Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Amphastar Pharmaceuticals	10.76%	14.98%	6.96%
Tarsus Pharmaceuticals	-7.67%	-13.53%	-8.12%

Summary

Amphastar Pharmaceuticals beats Tarsus Pharmaceuticals on 9 of the 16 factors compared between the two stocks.

How does Amphastar Pharmaceuticals compare to Arcutis Biotherapeutics?

Arcutis Biotherapeutics (NASDAQ:ARQT) and Amphastar Pharmaceuticals (NASDAQ:AMPH) are both healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their media sentiment, valuation, profitability, institutional ownership, earnings, dividends, risk and analyst recommendations.

In the previous week, Arcutis Biotherapeutics had 2 more articles in the media than Amphastar Pharmaceuticals. MarketBeat recorded 7 mentions for Arcutis Biotherapeutics and 5 mentions for Amphastar Pharmaceuticals. Amphastar Pharmaceuticals' average media sentiment score of 0.46 beat Arcutis Biotherapeutics' score of 0.46 indicating that Amphastar Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Arcutis Biotherapeutics	3 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Amphastar Pharmaceuticals	3 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Amphastar Pharmaceuticals has higher revenue and earnings than Arcutis Biotherapeutics. Amphastar Pharmaceuticals is trading at a lower price-to-earnings ratio than Arcutis Biotherapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Arcutis Biotherapeutics	$376.07M	8.47	-$16.14M	$0.21	120.69
Amphastar Pharmaceuticals	$719.89M	1.40	$98.09M	$1.69	13.98

Arcutis Biotherapeutics presently has a consensus target price of $35.57, suggesting a potential upside of 40.35%. Amphastar Pharmaceuticals has a consensus target price of $22.50, suggesting a potential downside of 4.74%. Given Arcutis Biotherapeutics' stronger consensus rating and higher possible upside, equities research analysts plainly believe Arcutis Biotherapeutics is more favorable than Amphastar Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Arcutis Biotherapeutics	0 Sell rating(s)	3 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.67
Amphastar Pharmaceuticals	2 Sell rating(s)	6 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.75

Arcutis Biotherapeutics has a beta of 1.5, indicating that its stock price is 50% more volatile than the broader market. Comparatively, Amphastar Pharmaceuticals has a beta of 0.92, indicating that its stock price is 8% less volatile than the broader market.

Amphastar Pharmaceuticals has a net margin of 10.76% compared to Arcutis Biotherapeutics' net margin of 6.15%. Arcutis Biotherapeutics' return on equity of 15.05% beat Amphastar Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Arcutis Biotherapeutics	6.15%	15.05%	6.51%
Amphastar Pharmaceuticals	10.76%	14.98%	6.96%

65.1% of Amphastar Pharmaceuticals shares are owned by institutional investors. 9.4% of Arcutis Biotherapeutics shares are owned by company insiders. Comparatively, 29.6% of Amphastar Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Summary

Arcutis Biotherapeutics and Amphastar Pharmaceuticals tied by winning 8 of the 16 factors compared between the two stocks.

How does Amphastar Pharmaceuticals compare to MBX Biosciences?

Amphastar Pharmaceuticals (NASDAQ:AMPH) and MBX Biosciences (NASDAQ:MBX) are both healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their analyst recommendations, earnings, dividends, institutional ownership, valuation, risk, media sentiment and profitability.

65.1% of Amphastar Pharmaceuticals shares are owned by institutional investors. 29.6% of Amphastar Pharmaceuticals shares are owned by company insiders. Comparatively, 31.1% of MBX Biosciences shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Amphastar Pharmaceuticals has a net margin of 10.76% compared to MBX Biosciences' net margin of 0.00%. Amphastar Pharmaceuticals' return on equity of 14.98% beat MBX Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Amphastar Pharmaceuticals	10.76%	14.98%	6.96%
MBX Biosciences	N/A	-26.02%	-24.94%

Amphastar Pharmaceuticals has a beta of 0.92, indicating that its share price is 8% less volatile than the broader market. Comparatively, MBX Biosciences has a beta of 0.04, indicating that its share price is 96% less volatile than the broader market.

Amphastar Pharmaceuticals has higher revenue and earnings than MBX Biosciences. MBX Biosciences is trading at a lower price-to-earnings ratio than Amphastar Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Amphastar Pharmaceuticals	$719.89M	1.40	$98.09M	$1.69	13.98
MBX Biosciences	N/A	N/A	-$86.97M	-$2.41	N/A

In the previous week, Amphastar Pharmaceuticals had 2 more articles in the media than MBX Biosciences. MarketBeat recorded 5 mentions for Amphastar Pharmaceuticals and 3 mentions for MBX Biosciences. Amphastar Pharmaceuticals' average media sentiment score of 0.46 beat MBX Biosciences' score of 0.45 indicating that Amphastar Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Amphastar Pharmaceuticals	3 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
MBX Biosciences	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Amphastar Pharmaceuticals presently has a consensus price target of $22.50, suggesting a potential downside of 4.74%. MBX Biosciences has a consensus price target of $77.00, suggesting a potential upside of 22.40%. Given MBX Biosciences' stronger consensus rating and higher possible upside, analysts clearly believe MBX Biosciences is more favorable than Amphastar Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Amphastar Pharmaceuticals	2 Sell rating(s)	6 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.75
MBX Biosciences	2 Sell rating(s)	0 Hold rating(s)	10 Buy rating(s)	1 Strong Buy rating(s)	2.77

Summary

Amphastar Pharmaceuticals beats MBX Biosciences on 11 of the 16 factors compared between the two stocks.

How does Amphastar Pharmaceuticals compare to MorphoSys?

Amphastar Pharmaceuticals (NASDAQ:AMPH) and MorphoSys (NASDAQ:MOR) are both healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their media sentiment, dividends, profitability, valuation, institutional ownership, risk, earnings and analyst recommendations.

65.1% of Amphastar Pharmaceuticals shares are held by institutional investors. Comparatively, 18.4% of MorphoSys shares are held by institutional investors. 29.6% of Amphastar Pharmaceuticals shares are held by company insiders. Comparatively, 0.1% of MorphoSys shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Amphastar Pharmaceuticals has a beta of 0.92, suggesting that its stock price is 8% less volatile than the broader market. Comparatively, MorphoSys has a beta of 1.2, suggesting that its stock price is 20% more volatile than the broader market.

In the previous week, Amphastar Pharmaceuticals had 5 more articles in the media than MorphoSys. MarketBeat recorded 5 mentions for Amphastar Pharmaceuticals and 0 mentions for MorphoSys. Amphastar Pharmaceuticals' average media sentiment score of 0.46 beat MorphoSys' score of 0.00 indicating that Amphastar Pharmaceuticals is being referred to more favorably in the media.

Company	Overall Sentiment
Amphastar Pharmaceuticals	Neutral
MorphoSys	Neutral

Amphastar Pharmaceuticals presently has a consensus target price of $22.50, suggesting a potential downside of 4.74%. Given Amphastar Pharmaceuticals' stronger consensus rating and higher possible upside, equities analysts clearly believe Amphastar Pharmaceuticals is more favorable than MorphoSys.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Amphastar Pharmaceuticals	2 Sell rating(s)	6 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.75
MorphoSys	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Amphastar Pharmaceuticals has higher revenue and earnings than MorphoSys. MorphoSys is trading at a lower price-to-earnings ratio than Amphastar Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Amphastar Pharmaceuticals	$719.89M	1.40	$98.09M	$1.69	13.98
MorphoSys	$238.28M	11.99	-$205.35M	-$3.48	N/A

Amphastar Pharmaceuticals has a net margin of 10.76% compared to MorphoSys' net margin of -226.79%. Amphastar Pharmaceuticals' return on equity of 14.98% beat MorphoSys' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Amphastar Pharmaceuticals	10.76%	14.98%	6.96%
MorphoSys	-226.79%	-694.31%	-22.55%

Summary

Amphastar Pharmaceuticals beats MorphoSys on 13 of the 15 factors compared between the two stocks.

Get Amphastar Pharmaceuticals News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding AMPH and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

AMPH vs. The Competition

Export

Metric	Amphastar Pharmaceuticals	Pharmaceuticals Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$1.01B	$12.48B	$7.26B	$13.14B
Dividend Yield	N/A	2.63%	2.57%	12.30%
P/E Ratio	13.98	797.25	275.79	25.40
Price / Sales	1.40	950.97	695.58	114.47
Price / Cash	5.60	88.44	77.42	51.66
Price / Book	1.38	10.53	10.46	6.33
Net Income	$98.09M	$2.82B	$3.49B	$358.33M
7 Day Performance	-0.67%	1.69%	0.59%	1.12%
1 Month Performance	8.65%	0.83%	-2.01%	-2.67%
1 Year Performance	-14.54%	3.90%	18.09%	6.01%

Amphastar Pharmaceuticals Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
AMPH Amphastar Pharmaceuticals	1.8361 of 5 stars	$23.62 -0.8%	$22.50 -4.7%	-13.9%	$1.01B	$719.89M	13.98	1,976	News Coverage Insider Trade High Trading Volume
OGN Organon & Co.	1.2593 of 5 stars	$13.68 +0.2%	$11.40 -16.6%	+26.0%	$3.59B	$6.13B	17.76	10,000
TARS Tarsus Pharmaceuticals	2.9342 of 5 stars	$78.23 -2.2%	$92.57 +18.3%	+44.5%	$3.43B	$606.33M	N/A	50	Analyst Upgrade Insider Trade
ARQT Arcutis Biotherapeutics	3.6251 of 5 stars	$23.51 -3.1%	$35.57 +51.3%	+43.1%	$2.96B	$463.98M	111.96	354	News Coverage Positive News Gap Up High Trading Volume
MBX MBX Biosciences	2.6148 of 5 stars	$61.08 +2.7%	$77.00 +26.1%	+524.7%	$2.94B	N/A	N/A	63	Positive News

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:AMPH) was last updated on 9/19/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Amphastar Pharmaceuticals (AMPH) Competitors

AMPH vs. OGN, TARS, ARQT, MBX, and MOR

How does Amphastar Pharmaceuticals compare to Organon & Co.?

Summary

How does Amphastar Pharmaceuticals compare to Tarsus Pharmaceuticals?

Summary

How does Amphastar Pharmaceuticals compare to Arcutis Biotherapeutics?

Summary

How does Amphastar Pharmaceuticals compare to MBX Biosciences?

Summary

How does Amphastar Pharmaceuticals compare to MorphoSys?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

AMPH vs. The Competition

Amphastar Pharmaceuticals Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Amphastar Pharmaceuticals (AMPH) Competitors

AMPH vs. OGN, TARS, ARQT, MBX, and MOR

How does Amphastar Pharmaceuticals compare to Organon & Co.?

Do analysts recommend OGN or AMPH?

Which has better earnings and valuation, OGN or AMPH?

Does the media refer more to OGN or AMPH?

Do insiders & institutionals have more ownership in OGN or AMPH?

Which has more volatility and risk, OGN or AMPH?

Is OGN or AMPH more profitable?

Summary

How does Amphastar Pharmaceuticals compare to Tarsus Pharmaceuticals?

Do analysts prefer AMPH or TARS?

Do insiders & institutionals have more ownership in AMPH or TARS?

Which has higher earnings and valuation, AMPH or TARS?

Does the media favor AMPH or TARS?

Which has more volatility and risk, AMPH or TARS?

Is AMPH or TARS more profitable?

Summary

How does Amphastar Pharmaceuticals compare to Arcutis Biotherapeutics?

Does the media prefer ARQT or AMPH?

Which has better valuation and earnings, ARQT or AMPH?

Do analysts prefer ARQT or AMPH?

Which has more volatility & risk, ARQT or AMPH?

Is ARQT or AMPH more profitable?

Do insiders and institutionals have more ownership in ARQT or AMPH?

Summary

How does Amphastar Pharmaceuticals compare to MBX Biosciences?

Do insiders and institutionals have more ownership in AMPH or MBX?

Is AMPH or MBX more profitable?

Which has more volatility and risk, AMPH or MBX?

Which has better valuation & earnings, AMPH or MBX?

Does the media favor AMPH or MBX?

Do analysts recommend AMPH or MBX?

Summary

How does Amphastar Pharmaceuticals compare to MorphoSys?

Do insiders & institutionals have more ownership in AMPH or MOR?

Which has more risk and volatility, AMPH or MOR?

Does the media favor AMPH or MOR?

Do analysts rate AMPH or MOR?

Which has higher valuation and earnings, AMPH or MOR?

Is AMPH or MOR more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

AMPH vs. The Competition

Amphastar Pharmaceuticals Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools